Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.58
+2.3%
$5.02
$3.42
$7.20
$255.21M1.751.57 million shs708,073 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$4.98
+2.2%
$3.82
$2.41
$10.37
$389.90M2.341.19 million shs702,337 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$4.23
-0.7%
$3.47
$1.87
$11.40
$377.30M-0.111.47 million shs263,302 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$2.03
-0.7%
$2.28
$1.90
$4.21
$58.31M0.61177,661 shs107,238 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+10.24%-17.86%+14.09%-6.63%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
0.00%+5.42%+29.58%+59.49%-16.65%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%+10.44%+20.51%+101.43%-38.34%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%+2.79%-15.27%-13.83%-38.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2834 of 5 stars
0.01.00.00.02.10.80.6
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.3141 of 5 stars
4.62.00.00.01.91.70.6
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.9532 of 5 stars
3.31.00.04.12.53.30.0
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.4012 of 5 stars
0.05.00.00.00.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.10203.46% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63269.39% Upside
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest VTGN, TERN, ACB, and SLDB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/18/2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.00
5/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.04$0.62 per share7.43$7.78 per share0.59
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M47.67N/AN/A$3.43 per share1.45
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.07 per shareN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$490K120.51N/AN/A$2.44 per share0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1141.5910.40N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$88.85M-$1.09N/AN/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)

Latest VTGN, TERN, ACB, and SLDB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
6/17/2025Q4 2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
10.89
10.89
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
30.89
30.89
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
6.51
6.51

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.21 million56.21 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.51 million76.04 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million86.03 millionNot Optionable
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4029.16 million28.78 millionOptionable

Recent News About These Companies

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha
Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.58 +0.11 (+2.35%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$4.57 -0.01 (-0.22%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$4.98 +0.11 (+2.18%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$5.03 +0.05 (+0.98%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$4.23 -0.03 (-0.70%)
As of 07/3/2025 02:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$2.02 -0.02 (-0.74%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$2.03 +0.00 (+0.25%)
As of 07/3/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.